Genomics & Informatics10.5808/gi.220512022203e29The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patientsChoong-kun Lee, Hong Jae Chon, Woo Sun Kwon, Hyo-Jeong Ban, Sang Cheol Kim, Hyunwook Kim, Hei-Cheul Jeung, Jimyung Chung, Sun Young Rha,,
Cancer10.1002/cncr.339712021127224122-4123Pricing transparency among several needs for patients with high‐risk breast cancerAshley Hay,,
BMJ10.1136/bmj.h41342015h4134Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population,
Gastric Cancer10.1007/s10120-010-0553-42010133155-161Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trialMichael Gubanski, , Anders Johnsson, Eva Fernebro, Lianna Kadar, Ingegerd Karlberg, Petra Flygare, Åke Berglund, Bengt Glimelius, Pehr A. Lind,,
Pediatric Blood & Cancer10.1002/pbc.242052012602242-247Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: A report on toxicity and efficacy from a prospective pilot phase II studyKavita V. Dharmarajan, Leonard H. Wexler, Suzanne L. Wolden,,
Journal of Gastric Cancer10.5230/jgc.2022.22.e720222211Predicting the Bleeding Risk for Patients on Anticoagulant Therapy Prior to Gastric Endoscopic Submucosal DissectionJie-Hyun Kim,,
Gastric Cancer10.1007/s10120-006-0379-2200693203-207Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancerShinya Ueda, Shuichi Hironaka, Narikazu Boku, Akira Fukutomi, Takayuki Yoshino, Yusuke Onozawa,,
Gastric Cancer10.1007/s10120-011-0030-82011143226-233A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial)Tetsuya Hamaguchi, , Kuniaki Shirao, Atsushi Ohtsu, Ichinosuke Hyodo, Yasuaki Arai, Hiroya Takiuchi, Hirofumi Fujii, Motoki Yoshida, Hiroshi Saito, Tadamichi Denda, Wasaburo Koizumi, Hiroaki Iwase, Narikazu Boku,,,
Medical Oncology10.1007/s12032-013-0630-82013303Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patientsJing Gao, Jun Zhou, Yanyan Li, Zhi Peng, Yilin Li, Xicheng Wang, Lin Shen,,
British Journal of Cancer10.1038/sj.bjc.66044612008992275-282UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group studyD M Kweekel, H Gelderblom, T Van der Straaten, N F Antonini, C J A Punt, H-J Guchelaar,,